Drug Trial Radar · NCT03981796
A Study to Evaluate Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel in Participants With Recurrent or Primary Advanced Endometrial Cancer
Last checked: Nov 19, 2026Latest source record: Sep 3, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
785
Actual
Start
Jul 18, 2019
Primary completion
Nov 26, 2026
Study completion Nov 26, 2026
Sponsor
- Lead sponsor
- Tesaro, Inc.GSK (GSK)
- Sponsor type
- Industry
- Collaborators
- European Network of Gynaecological Oncological Trial Groups (ENGOT); GOG Foundation
- First posted
- Jun 11, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a 2 part study. Part 1 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab versus placebo plus carboplatin-paclitaxel followed by placebo; and Part 2 is to evaluate the efficacy and safety of dostarlimab plus carboplatin-paclitaxel followed by dostarlimab plus niraparib versus placebo plus carboplatin-paclitaxel followed by placebo in participants with recurrent or primary advanced (Stage III or IV) endometrial cancer.
Conditions
- Neoplasms
Interventions
DostarlimabBiological
Participants will be administered dostarlimab
Placebo matching dostarlimabDrug
Participants will be administered placebo matching dostarlimab
CarboplatinDrug
Participants will be administered carboplatin
PaclitaxelDrug
Participants will be administered paclitaxel
NiraparibDrug
Participants will be administered niraparib
Placebo matching NiraparibDrug
Participants will be administered placebo matching Niraparib
Primary outcomes
What the sponsor says the trial is designed to measure.
- Parts 1 and 2: Progression-Free Survival (PFS) - investigator assessmentTime frame: Up to 6 years
- Part 1: Overall survivalTime frame: Up to 6 years
Locations
169 sites in 20 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Phoenix, Arizona
GSK Investigational Site
Scottsdale, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Tucson, Arizona
GSK Investigational Site
Newport Beach, California
GSK Investigational Site
Palo Alto, California
GSK Investigational Site
Deerfield Beach, Florida
GSK Investigational Site
Jacksonville, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Orlando, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Augusta, Georgia
GSK Investigational Site
Savannah, Georgia
GSK Investigational Site
Hinsdale, Illinois
GSK Investigational Site
Zion, Illinois
GSK Investigational Site
Fort Wayne, Indiana
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Indianapolis, Indiana
GSK Investigational Site
Iowa City, Iowa
GSK Investigational Site
Lexington, Kentucky
GSK Investigational Site
Covington, Louisiana
GSK Investigational Site
New Orleans, Louisiana
GSK Investigational Site
Shreveport, Louisiana
GSK Investigational Site
Boston, Massachusetts
GSK Investigational Site
Springfield, Massachusetts
GSK Investigational Site
Detroit, Michigan
GSK Investigational Site
St Louis, Missouri
GSK Investigational Site
Lebanon, New Hampshire
GSK Investigational Site
Albuquerque, New Mexico
GSK Investigational Site
Rio Rancho, New Mexico
GSK Investigational Site
Albany, New York
GSK Investigational Site
Mineola, New York
GSK Investigational Site
New York, New York
GSK Investigational Site
The Bronx, New York
GSK Investigational Site
Charlotte, North Carolina
GSK Investigational Site
Durham, North Carolina
GSK Investigational Site
Kernersville, North Carolina
GSK Investigational Site
Mount Airy, North Carolina
GSK Investigational Site
Winston-Salem, North Carolina
Showing 40 of 169 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.